• ARCHIMED is investing in Canadian nutraceutical company Organika through its MED III and MED IV funds.
• Organika is MED IV's first investment; the fund closed at €1.5 billion in September 2026.
• The partnership will support research, product innovation and expansion into new sales channels and markets.
• Aaron Chin will remain CEO.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Archimed SAS published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.